Mission Bio Tapestri Single-Cell MRD AML Multiomics Assay

Mission Bio has launched a single-cell, multiomics, minimal residual disease (MRD) assay for acute myeloid leukemia (AML) on its Tapestri platform. The assay interrogates DNA and protein targets at single-cell resolution and characterizes genotypic and immunophenotypic changes over the course of disease. It identifies patients with recurrent AML and potentially offers clinicians actionable treatment targets. Targets include 40 genes for single-cell DNA sequencing based on current international AML MRD guidelines, such as European LeukemiaNet, and a 17-plex antibody-oligonucleotide conjugate panel curated for key biomarkers associated with AML MRD.